Quantifying Health Utilities in Patients Undergoing Stereotactic Body Radiation Treatment for Liver Metastases for Use in Future Economic Evaluations. Issue 9 (September 2017)

• Record Type: Journal Article
• Authors: Warren, B.; Munoz–Schuffenegger, P.; Chan, K.K.W.; Chu, W.; Helou, J.; Erler, D.; Chung, H.
• Is Part Of: Clinical oncology. Volume 29:Issue 9(2017)
• Page Start: e141
• Page End: e147
• Publication Date: 2017-09
• Subjects: Health utility score -- liver metastases -- quality of life -- stereotactic body radiation treatment; Oncology -- Periodicals; Tumors -- Periodicals; Cancer -- Treatment -- Periodicals; Radiotherapy -- Periodicals; Neoplasms -- Periodicals; Cancer -- Radiotherapy; Cancer -- Treatment; Oncology; Medical radiology; Radiotherapy; Tumors; Electronic journals; Periodicals; 616.994
• DOI: 10.1016/j.clon.2017.03.011
• Languages: English
• ISSNs: 0936-6555

Abstract

Abstract: Aim: Stereotactic body radiation therapy (SBRT) is increasingly used as an option for those with liver metastases. In order to facilitate future economic impact of health technologies, health utility scores may be used. The EuroQOL-5D-3L (EQ-5D) preference-based healthy utility instrument was used to evaluate the impact of treatment with SBRT on health utility scores. Materials and methods: Between August 2013 and October 2014, 31 patients treated with 3–5 fractions of SBRT for liver metastases were enrolled in this study. The EQ-5D instrument was administered at baseline, during and up to 6 months post-SBRT. Results: Mean EQ-5D score at baseline was 0.857, which remained stable across the entire study time period. Transient increases in difficulties with mobility (9.7% reported at baseline to 16.1% on the last day of treatment) and usual activities (3.2% reported at baseline to 34.5% on day two) were found during the course of treatment; these returned to baseline levels subsequently. The mean visual analogue score at baseline was 65.8 and remained unchanged throughout treatment and follow-up. Conclusions: The stability of health utility scores and problems reported by patients undergoing treatment indicate that SBRT for liver metastases does not impart a significant adverse effect on quality of life. These results may be used for future economic evaluation of SBRT. Highlights: Stereotactic body radiation treatment (SBRT) is increasingly being used in the treatment of liver metastases. There are few data on the effect on quality of life surrounding treatment with SBRT for liver metastases. In our cohort, liver SBRT was well tolerated; it did not affect pain, mobility, self-care, or anxiety and depression scores. These results will provide valuable information to help with the economic evaluation of SBRT for liver metastases. Future studies are needed to investigate the long-term survival benefits of this technology.